CEO Lukas Schüpbach has decided to step down from his role at Bacthera, effective August 31st, 2023
Lukas Schüpbach has been with the company since 2020. Lukas has played a critical role in the establishment of Bacthera as a leading global end-to-end contract development and manufacturing service provider in the Live Biotherapeutics industry with clinical and commercial manufacturing sites in Switzerland, Denmark, and Spain
As of September 1st, 2023, Christian Eberle has been appointed as CEO. Christian brings significant experience to the Bacthera team, having previously served as the CEO of Evitria AG, a Swiss-based CRO. Christian began his career at Bain Consulting and has held various leadership positions at Roche and Lonza. Christian holds a PhD and a Master of Sciences in Chemistry from ETH Zurich.
Lukas Schüpbach commented: “I am very proud of what we have jointly achieved since the inception of the company, setting up a global end-to-end CDMO, in the new industry for Live Biotherapeutic Products (LBP). I’m looking forward to seeing from the outside how Bacthera is growing in the LBP space and wish the company great success”.
Mauricio Graber, Chairman of Bacthera AG commented: “I would like to thank Lukas for his strong contribution to establishing Bacthera as a leading player in the LBP space and not least his instrumental role in the collaboration with Seres Therapeutics to set up a commercial manufacturing facility in Visp, Switzerland for the production of the first-ever FDA-approved oral LBP. At the same time, I would like to welcome Christian to Bacthera and on behalf of the Board of Directors we look forward to working with Christian in securing the future profitable growth of Bacthera”.
Christian Eberle, incoming CEO of Bacthera commented: “I am honored and privileged to lead Bacthera during this exciting chapter. I am grateful for the opportunity and excited to embark on this journey with the exceptional team at Bacthera."
Bacthera is a joint venture between Chr. Hansen and Lonza that was founded end of 2019.
Kindly direct any media requests directly to Bacthera.
科 汉森是一家全球性且具备差异化的生物科技公司，为食品行业、营养行业、制药行业和畜牧业开发天然原料的解决方案。 在科 汉森，我们拥有独特的优势，可通过微生物解决方案推动积极的变革。 在过去超过 150 年的时间里，我们致力于实现可持续的农业、更好的食品以及让全世界更多的人过上更健康的生活。 我们的微生物和发酵技术平台拥有改变规则的潜力，库存广泛且价值重大，包括约 50,000 种微生物菌株。 除了适应客户需求和全球趋势外，我们还将挖掘释放有益菌的力量，以应对食物浪费、全球健康以及抗生素和杀虫剂滥用等全球挑战。 作为全世界最具可持续性的生物技术公司，我们每天影响超过 10 亿人的生活。 受我们的创新传统与对前沿科学的求知驱动，公司宗旨“To grow a better world. Naturally.”体现在我们的所有工作中。